Step by Step

INTRODUCTION

10/18/2016 - Medical Grand Rounds: Gene Therapy for Sickle Cell Disease: Scientific Fact or Science Fiction?

QUIZ

EVALUATION

CERTIFICATE

INTRODUCTION

Credit Hours: CME 1.00

Target Audience:

Faculty, residents, fellows, and community physicians in General Internal Medicine and subspecialties.

Educational Objectives:

Upon completion of this activity, participants should be able to:

  • Increase patient treatment options with gene therapy.
  • Improve patient education with gene therapy information.
  • Improve diagnostic skills for recognizing high risk sickle cell disease.

Suggested Additional Reading:

  1. Goodman MA, Malik P. The potential of gene therapy approaches for the treatment of hemoglobinopathies: achievements and challenges. Ther Adv Hematol. 2016 Oct;7(5):302-315. Review. PubMed PMID: 27695619.
  2. The Lancet Haematology. Gene therapy for sickle cell disease. Lancet Haematol. 2016 Oct;3(10):e446. doi: 10.1016/S2352-3026(16)30130-2. PubMed PMID: 27692301.
  3. Traxler EA, Yao Y, Wang YD, Woodard KJ, Kurita R, Nakamura Y, Hughes JR, Hardison RC, Blobel GA, Li C, Weiss MJ. A genome-editing strategy to treat β-hemoglobinopathies that recapitulates a mutation associated with a benign genetic condition. Nat Med. 2016 Sep;22(9):987-90. doi: 10.1038/nm.4170. Epub 2016 Aug 15. PubMed PMID: 27525524.

Authors:
Brett Kaufman, PhD — Associate Professor of Medicine Division of Cardiology
No relationships with industry relevant to the content of this educational activity have been disclosed.
Greg Kato, MD — Professor of Medicine Division of Hematology/Oncology Director, Sickle Cell Center of Excellence
Dr. Kato receives Grant/Research support from Bayer AG. He is a consultant for Mast Therapeutics.
No other members of the planning committee, speakers, presenters, authors, content reviewers and/or anyone else in a position to control the content of this education activity have relevant financial relationships with any companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

The University of Pittsburgh School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The University of Pittsburgh School of Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Each physician should only claim credit commensurate with the extent of their participation in the activity.

Other health care professionals are awarded (0.1) continuing education units (CEU) which are equivalent to 1.0 contact hours.

The University of Pittsburgh is an affirmative action, equal opportunity institution.